PTN News and Press, Palatin Technologies Inc. From 02/29/24

A look at the top 10 most actives in the United States Marathon Digital Holdings Inc. (MARA) rose 2.4% to $31.03 on volume of 179,649,718 shares Vivani Medical Inc. (VANI) rose 270.3% to $3.74 on volume of 148,811,385 shares Nikola Corporation (NKLA) rose 1.7% to $0.7684 on volume of 121,...

A look at the top 10 most actives in the United States Marathon Digital Holdings Inc. (MARA) rose 1.8% to $30.87 on volume of 148,760,969 shares Vivani Medical Inc. (VANI) rose 291.9% to $3.9579 on volume of 141,227,838 shares Nikola Corporation (NKLA) rose 2.6% to $0.7758 on volume of 10...

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met , Statistical Significance (P<0.025) Multiple Secondary Symptom Endpo...

2024-02-15 14:49:08 ET Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Conference Call February 15, 2024, 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief O...

2024-02-15 07:34:29 ET More on Palatin Tech Palatin to raise ~$10M via securities offering Palatin rises as it completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171M Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data fo...

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) ...

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 PR Newswire CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal...

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE...

Palatin Announces Closing of $10 Million Registered Direct Offering PR Newswire CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medic...

2024-01-30 08:20:13 ET More on Palatin Tech Palatin rises as it completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171M Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data for Palatin Tech Read the full article on Seeki...